# India CRO Market

> 印度CRO市场研究报告信息按服务类型（临床试验、产品开发、工艺开发、上市后监测和质量监控等）、按治疗应用（肿瘤学、心血管、神经学、肾脏病和泌尿学及其他）、按最终用户（制药/生物制药公司、医疗设备公司和学术机构）以及按地区（印度） - 2025至2035年的增长与行业预测

- **Forecast Period:** 2025 - 2035
- **CAGR:** 6.0%
- **2024:** $ 6.32 Billion
- **2025:** $ 6.74 Billion
- **2035:** $ 12 Billion
- **Key Players:** Companies such as IQVIA (IN), Syneos Health (IN), PAREXEL International (IN), Covance (IN), Charles River Laboratories (IN), Medpace (IN), Clinipace (IN), KCR (IN), Pharmalex (IN) are some of the major participants in the market.

**Report ID:** MRFR/Pharma/2151-HCR · **Pages:** 70 · **Author:** Satyendra Maurya & Rahul Gotadki · **Last Updated:** September 15, 2026

**URL:** https://www.marketresearchfuture.com/reports/india-cro-market-2927

---

## Market Summary

## **India CRO Market Overview**

India CRO Market size was valued at USD 0.69 Billion in 2023. The CRO market industry is projected to grow from USD 0.73 Billion in 2024 to USD 1.32 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.23% during the forecast period (2024 - 2032). 

Clinical trials' globalization, the use of new technologies in clinical research, the rise in illness diversity and prevalence, and the expansion of R&D all support outsourcing, are the key market drivers enhancing the market growth. 

_Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review_

## **India CRO Market Trends**

### **Globalization of clinical trials is driving the market growth**

The primary drivers anticipated to propel the market are the globalisation of clinical trials, adoption of new technologies in clinical research, rising illness diversity and prevalence, and rising research and development encouraging outsourcing. The Indian government is actively pursuing improvements to R&D efforts, which is anticipated to foster market expansion. 

In 2024, the Indian pharmaceutical sector is focused on reducing drug approval times by up to 50%, aiming to accelerate innovation and market entry for new therapies. The Department of Pharmaceuticals, alongside CDSCO, continues enhancing regulatory processes, supporting faster approvals for innovative drugs and biologics. This initiative is part of India's broader push to shift from a generics market to a more innovation-driven economy. 

With increased focus on R&D, local manufacturing, and indigenization, the country is positioning itself as a global leader in pharmaceutical development​.

The digitalization of [clinical trials](../../../reports/clinical-trials-market-7787) is expected to accelerate market expansion. Digitalization has improved the efficiency of a number of trial procedures, including data collection, regulatory compliance, logistics, and supply management, among others. Additionally, the advent of digital therapies has made it simpler than ever to collect real-time data on safety and toxicity, supporting quick trial design correction and fostering market expansion. 

Clinical trials in India cost about half as much as they do in the United States and Europe. Therefore, it is projected that the county will dominate the market because to its cost effectiveness and big patient pool of untreated patients.

As of 2024, India's clinical research sector has experienced a significant recovery and transformation following the disruptions caused by the COVID-19 pandemic. In the early stages of the pandemic, research and development activities were halted due to supply chain disruptions and the temporary closure of manufacturing facilities.

Additionally, lockdowns resulted in a sharp decline in patient recruitment for clinical studies. However, the urgent need for COVID-19 treatments and vaccines spurred a resurgence in clinical trials by 2021, marking a positive shift in the sector.

India has emerged as a key hub for clinical trials, particularly in the areas of vaccine development, oncology, and emerging therapeutics. This is due to its vast patient population, advancing healthcare infrastructure, and the increasing adoption of digital technologies such as decentralized clinical trials (DCTs). These factors have been pivotal in driving the recovery and continued growth of India's clinical trial market.

Notably, global pharmaceutical companies, as well as domestic firms, are continuing to invest heavily in India's clinical trial ecosystem. Recent reports confirm that the country has maintained a steady pace of trial activities, with many international sponsors choosing India for Phase II and III trials, benefiting from the large, diverse patient base and cost advantages​.

## **India CRO Market Segment Insights**

### **India CRO Service Type Insights**

The India CRO market segmentation, based on service type, includes clinical trials, product development, process development, post-marketing surveillance, and quality monitoring others. Clinical trials segment dominated the market in 2022. This is explained by the segment's high cost structure. One of the main factors contributing to the high cost of this experiment is the requirement for a big patient group in phase clinical studies. 

Additionally, the investigations in clinical trials are conducted for a longer period of time, which lowers the trial's cost and raises its market segment share.

### **India CRO Therapeutic Application Insights**

The India CRO market segmentation, based on application, includes oncology, cardiovascular, neurology, nephrology and urology, and others. Oncology segment dominated the market in 2022. This is due to the rising incidence of cancer in the nation and the rising demand for cutting-edge medical technology and cancer therapies. 

The Cancer Tomorrow projects that by 2040, 2 million people in India will be affected by cancer, which is one of the leading causes of death in the world. The majority of cancer treatments are ineffective when the disease is advanced, which is a major factor in the nation's rising demand for novel cancer therapy choices.

### **India CRO End User Insights**

The India CRO market segmentation, based on end user, includes pharmaceutical/biopharmaceutical companies, [medical devices](../../../reports/medical-devices-market-2869) companies, and academic institutes. Pharmaceutical/biopharmaceutical companies segment dominated the India CRO market in 2022.This is due to India's expanding CRO adoption.

**Figure 1: India CRO Market, by End User, 2023 & 2032 (USD Billion)** 

Source_**: Secondary Research, Primary Research, MRFR Database and Analyst Review**_

### **India CRO Regional Insights**

By region, the study provides the market insights into India. This is due to the accessibility of a sizable patient pool that makes recruitment simple. One of the main factors influencing the industry is the global pandemic. Due to the high quality and speedy turnaround of its studies, India's largest, most experienced biotech CRO, "Novotech," has observed a rise in demand from biotechnology sponsors. 

For COVID-19 studies, an increasing number of biotechnology companies choose India because of the country's vast patient pool and quick processes.

## **India CRO Key Market Players & Competitive Insights**

Leading market players are investing heavily in research and development in order to expand their product lines, which will help the CRO market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, CRO industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the India CRO industry to benefit clients and increase the market sector. In recent years, the CRO industry has offered some of the most significant advantages to medicine. 

Major players in the CRO market, including Quintiles IMS Holdings, Inc., Syngene, Pharmaceutical Product Development, LLC., Siro Clinpharm, Clininvent Research Pvt. Ltd., VIMTA, Bilcare Limited, Aizant Drug Research Solutions Private Limited, Piramal Pharma Solutions, Synapse Labs Pvt Limited, Eurofins Scientific, Laurus Labs., Neuland Laboratories Ltd, and PAREXEL International Corporation, are attempting to increase market demand by investing in research and development End Users.

Operating a life sciences research organisation with the goal of providing clinical research and development services is Aragen Life Sciences. As a result of the company's expertise in drug research, clinical development, contract manufacturing, formulation, and informatics, healthcare organisations are able to provide a wide range of cutting-edge healthcare goods and services. 

In order to broaden its end-to-end comprehensive discovery and development platform for the biotechnology, pharmaceuticals, and other industries, Aragen Life Sciences, an Indian CRO, purchased Intox Pvt. Ltd. in Maharashtra.

Developer of the crystallizable fragment (Fc)-fusion protein platform for the production of novel kinds of biological therapies for the treatment of diabetes is Akston Biosciences. The business produces kilogram-scale batches of medicinal ingredients and provides vaccinations, ultra-long-acting insulins, and treatments for autoimmune diseases, enabling physicians to enhance glucose management, lessen consequences, and completely remove the risk of hypoglycemia for both human and animal health. 

In 2024, Akston Biosciences is continuing its progress with its second-generation COVID-19 vaccine, AKS-452, in India. The vaccine has successfully completed Phase II/III clinical trials, demonstrating a robust safety profile and an impressive 91% seroconversion rate at Day 56.

This vaccine, which is notable for its room-temperature stability, has shown promising results in protecting against variants like Delta and Omicron.

In 2023, Akston took back control over the licensing and commercialization of AKS-452 after ending its partnership with Stelis Biopharma, and is now working with a new contract development and manufacturing organization (CDMO) in India to continue its development​.

This vaccine is especially significant for low- and middle-income countries, as it does not require cold-chain storage, making it easier to distribute in regions with limited infrastructure. Additionally, AKS-452 is being explored as a potential "universal" booster, which has shown to increase neutralizing antibody titers in individuals previously vaccinated with other COVID-19 vaccines​.

### **Key Companies in the India CRO market include**

- Quintiles IMS Holdings, Inc.
- Syngene
- Siro Clinpharm
- Clininvent Research Pvt. Ltd.
- VIMTA
- Bilcare Limited
- Aizant Drug Research Solutions Private Limited
- Piramal Pharma Solutions
- Synapse Labs Pvt Limited
- [Eurofins Scientific](https://www.eurofins.com/media-centre/safeharborstatement/)
- Laurus Labs.
- Neuland Laboratories Ltd
- [PAREXEL International Corporation](https://newsroom.parexel.com/news-releases/news-release-details/parexel-appoints-susan-r-salka-board-directors)

## **India CRO Industry Developments**

IQVIA (Quintiles IMS Holdings) remains a frontrunner in India's CRO industry by leveraging big data analytics and advanced clinical trial solutions. Their platform enhances real-time insights and optimizes clinical trials, significantly reducing time-to-market for pharmaceuticals. Their innovation in Clinical Trial Data Management continues to push the boundaries of efficiency and precision in drug development​.

Syngene International has strengthened its position as a leader in drug discovery, development, and manufacturing services. The company expanded its research and development capacity in 2023 by opening a state-of-the-art biotechnology facility in Bangalore.

Syngene's collaboration with Bristol Myers Squibb focuses on advanced research in oncology and immuno-oncology, driving the development of next-generation therapies​.

Siro Clinpharm has been making notable strides in clinical pharmacology services, particularly with the launch of an enhanced Clinical Trials Management System (CTMS). Their efforts in pharmacovigilance and safety monitoring are helping to ensure higher standards for patient safety during clinical trials, positioning them as a reliable partner for global pharmaceutical companies​.

Clininvent Research Pvt. Ltd., part of TCG Lifesciences, continues to offer end-to-end solutions for drug discovery, development, and commercialization. The company's focus on custom manufacturing and regulatory compliance, particularly through FDA-approved facilities, ensures that they meet the stringent quality requirements of the pharmaceutical industry. 

Their expertise in GMP (Good Manufacturing Practice) compliance and clinical trial management further solidifies their role in India's growing CRO ecosystem​

## **India CRO Market Segmentation**

### **India CRO Service Type Outlook**

- Clinical Trials
- Product Development
- Process Development
- Post-Marketing Surveillance
- Quality Monitoring Others

### **India CRO Therapeutic Application Outlook**

- Oncology
- Cardiovascular
- Neurology
- Nephrology and Urology
- Others

### **India CRO End User Outlook**

- Pharmaceutical/Biopharmaceutical Companies
- Medical Devices Companies
- Academic Institutes

## Market Drivers

### Growing Pharmaceutical Sector

印度合同研究组织市场正在经历显著增长，主要受到制药行业扩张的推动。截至2026年1月，印度在全球制药生产中排名前列，约占全球市场的3.6%。这一增长归因于对研发的投资增加，预计到2030年，印度制药行业将达到1300亿美元。
 
因此，合同研究组织（CRO）的需求可能会增加，因为制药公司寻求将临床试验和其他研究活动外包，以提高效率并降低成本。CRO与制药公司之间的合作预计将促进创新，加快药物开发过程，从而巩固印度合同研究组织市场在全球市场中的地位。

- 根据世界银行的数据，医疗支出在新兴经济体中持续增加，支持制药行业的扩张。对药物开发、制造和医疗创新的投资增加，正在为加速研究时间表和提高运营效率的CRO服务创造强劲需求。

### Increased Focus on Clinical Trials

印度合同研究组织市场正在见证国内临床试验数量的显著增加。截至2026年1月，印度因其多样化的患者群体和具有成本效益的服务，已成为临床研究的吸引目的地。2025年，印度注册的临床试验数量稳步上升，仅在2025年就报告了超过1000个试验。
 ;r>这一趋势得到了印度政府简化监管流程和提高临床试验审批时间的举措的进一步支持。因此，CRO可能在促进这些试验中发挥关键作用，提供患者招募、数据管理和合规等基本服务。对临床试验的日益重视预计将增强印度合同研究组织市场，使其成为全球临床研究领域的关键参与者。

- 通过PubMed索引的研究表明，全球临床试验活动稳步增长，特别是在新兴市场。印度多样化的患者群体和不断扩展的研究基础设施继续吸引跨国研究，增强了对专注于试验管理、患者招募和合规的CRO的需求。

### Rising Demand for Outsourcing Services

印度合同研究组织市场正在经历制药和生物技术公司对外包服务的需求上升。截至2026年1月，许多组织越来越认识到将研究活动外包给专业CRO的好处，这些CRO可以提供专业知识、降低运营成本，并加快新产品的上市时间。
 ;r>预计印度的外包市场将在未来五年内显著增长，预计年均增长率为12%。这一趋势是由于公司需要专注于核心竞争力，同时利用CRO在临床试验、数据分析和合规方面的能力。对外包的日益倾向可能会巩固印度合同研究组织市场作为全球研究领域关键参与者的角色。

- 根据健康指标与评估研究所的数据，全球慢性疾病负担的增加正在提高对新疗法和临床开发项目的需求。这一趋势促使制药公司将研究职能外包给CRO，从而实现更快的开发周期和成本效益的运营。

### Emergence of Biotech and Genomic Research

印度合同研究组织市场越来越受到生物技术和基因组研究兴起的影响。截至2026年1月，印度的生物技术初创企业和研究项目正在迅速增长，生物技术行业预计到2025年将达到1000亿美元。这一增长主要得益于基因组学、个性化医学和生物制药的进步。CRO在这一领域正成为重要合作伙伴，提供生物分析测试、临床试验管理和监管支持等专业服务。
 ;r>CRO与生物技术公司的合作可能会增强创新疗法和诊断的开发，从而使印度合同研究组织市场成为全球生物技术生态系统的重要贡献者。

- 世界银行的数据强调了新兴经济体对生物技术创新和生命科学基础设施的投资不断增加。对基因组医学、精准医疗和生物制品开发的日益重视为提供专业研究、生物分析测试和监管支持服务的CRO创造了重大机会。

### Government Support and Policy Initiatives

印度合同研究组织市场受益于强有力的政府支持和旨在促进研究与开发的有利政策倡议。截至2026年1月，印度政府实施了多项计划，以鼓励对生命科学领域的投资，包括税收优惠和研究项目的资金支持。
 ;r>国家生物技术发展战略的建立进一步加强了生物技术研究和开发的框架。这些举措可能会改善CRO的运营环境，使其能够扩展服务和能力。支持性的监管环境预计将吸引更多国际客户，从而增强印度合同研究组织市场在全球舞台上的地位。

- 通过PubMed获得的研究强调，支持性的监管改革和政府支持的研究倡议提高了临床研究的生产力。增强的政策框架鼓励更多国内和国际参与者参与印度的研究生态系统，惠及多个治疗领域的CRO服务提供商。

## Future Outlook

印度合同研究组织市场预计在2025年至2035年期间以6.0%的年均增长率增长，推动因素包括研发投资增加和监管支持。

到2035年，市场预计将巩固其在临床研究服务中的领导地位。

## Segment Insights

### 按应用：临床试验（最大）与监管事务（增长最快）

在印度合同研究组织市场中，应用细分显示出市场份额在其组成部分之间的多样化分布。临床试验占据了58%的最大份额，这得益于新药批准数量的增加以及各个治疗领域的临床研究活动。另一方面，监管事务虽然份额较小，但随着公司寻求有效应对复杂的监管环境，正迅速获得关注和重视。

IQVIA继续通过先进的试验管理和分析解决方案支持大规模的临床开发项目。预计到2024年，临床试验在印度CRO市场中占据约58%的份额，推动因素包括药物开发活动的增加、赞助商外包的增长以及参与跨国研究的扩展。

### 按服务类型：制药服务（最大）与生物技术服务（增长最快）

在印度合同研究组织（CRO）市场中，制药服务占据了63%的显著份额，成为行业的基石。这种服务类型涵盖了广泛的研究和开发活动，使制药公司能够高效地创新并将药物推向市场。相反，生物技术服务作为一个快速扩展的细分市场，受到生物研究进展和生物制药投资增加的推动，突显了这一领域在印度医疗保健格局中日益重要的地位。

Syneos Health继续通过综合临床和商业化服务扩展制药开发能力。制药服务在2024年占据了市场收入的约63%，得益于制药研发支出的增加、临床试验活动的上升以及全球药品制造商对外包的强劲需求。

### 按最终用途：制药公司（最大）与生物技术公司（增长最快）

在印度合同研究组织市场中，市场份额的分布主要由制药公司主导，市场份额达到67%，这得益于它们广泛的研发需求和显著的预算分配。生物技术公司紧随其后，随着创新和个性化医疗的重要性不断上升，逐渐获得更大的份额。政府组织和学术机构占据市场的较小部分，但它们在研究和开发倡议中发挥着关键作用，弥补知识和应用之间的差距。

制药公司：主导 vs. 生物技术公司：新兴

制药公司在印度合同研究组织市场中代表着主导力量，利用庞大的资源进行药物开发和临床试验。考虑到它们复杂的产品管道和遵循严格的监管标准，它们对外包研究的需求是巨大的。相反，生物技术公司被视为新兴参与者，尤其在小众治疗领域和创新生物制造技术方面经历快速增长。这一增长主要受到基因研究进展和对生物制品需求增加的推动。两个细分市场展示了独特的特征：制药公司对于成熟产品至关重要，而生物技术公司则常常处于突破性发展的前沿。

## Regional Market Share Analysis

根据地区，研究提供了印度市场的洞察。这是由于可接触到大量患者群体，使招募变得简单。全球大流行是影响行业的主要因素之一。由于其研究的高质量和快速周转，印度最大的、经验最丰富的生物技术CRO“Novotech”观察到来自生物技术赞助商的需求上升。

对于COVID-19研究，越来越多的生物技术公司选择印度，因为该国拥有庞大的患者群体和快速的流程。

## Competitive Benchmarking

印度合同研究组织市场的竞争格局动态，受到对临床试验和研究服务需求增加的驱动。关键参与者积极追求强调创新、区域扩展和数字化转型的战略。例如，IQVIA（印度）通过利用先进的分析和技术来提高临床试验效率，确立了自己的领导地位。同样，Syneos Health（印度）专注于综合生物制药解决方案，使其能够满足多样化的客户群，同时优化运营流程。这些战略取向不仅增强了他们的市场存在感，还促进了更具竞争力的环境，因为公司努力通过服务提供和技术进步来区分自己。
在商业战术方面，公司越来越多地本地化其运营，以更好地服务于印度市场。这包括优化供应链和与当地公司建立合作伙伴关系，以增强服务交付。市场似乎适度分散，几家参与者争夺市场份额。然而，像PAREXEL International（印度）和Covance（印度）等主要公司的集体影响表明，随着公司寻求增强其能力并扩大地理覆盖范围，合并的趋势正在形成。
在2025年12月，PAREXEL International（印度）宣布与一家领先的印度生物技术公司建立战略合作伙伴关系，以增强其在该地区的临床试验能力。这一合作预计将简化流程并改善患者招募，从而提高临床试验的效率。这种合作伙伴关系表明了一种更广泛的趋势，即公司与当地实体对齐，以利用区域专业知识和资源。
在2025年11月，Covance（印度）推出了一个新的数字平台，旨在改善临床试验的数据管理和分析。这一举措强调了数字化转型在行业中的日益重要性，因为公司寻求利用技术来提高运营效率和数据准确性。这类平台的推出可能会为临床研究中的数据处理设定新的标准，使Covance成为市场上前瞻性的参与者。
在2025年10月，Charles River Laboratories（印度）扩大了其在印度的实验室设施，专注于增强其临床前和临床研究能力。这一扩展反映了其满足该地区对全面研究服务日益增长的需求的承诺。通过对基础设施的投资，Charles River Laboratories旨在巩固其市场地位，并满足客户不断变化的需求。
截至2026年1月，合同研究组织市场的竞争趋势越来越多地受到数字化、可持续性和人工智能整合的定义。战略联盟变得越来越普遍，因为公司认识到合作在增强服务提供和运营效率方面的价值。展望未来，竞争差异化似乎将越来越依赖于创新和技术，而不仅仅是价格。对供应链可靠性和先进技术解决方案的重视可能会塑造市场的未来格局。

## Recent News & Developments

[IQVIA](https://ichgcp.net/cro-list/country/india/company/iqvia)（Quintiles IMS Holdings）通过利用大数据分析和先进的临床试验解决方案，仍然是印度CRO行业的领军者。他们的平台增强了实时洞察力并优化了临床试验，显著缩短了药品上市时间。他们在临床试验数据管理方面的创新继续推动药物开发的效率和精确度的边界。

Syngene International已加强其在药物发现、开发和制造服务方面的领导地位。该公司在2023年通过在班加罗尔开设一座最先进的生物技术设施，扩大了其研发能力。

Syngene与Bristol Myers Squibb的合作专注于肿瘤学和免疫肿瘤学的先进研究，推动下一代疗法的发展。

Siro Clinpharm在临床药理服务方面取得了显著进展，特别是推出了增强的临床试验管理系统（CTMS）。他们在药物警戒和安全监测方面的努力有助于确保临床试验期间更高的患者安全标准，使他们成为全球制药公司的可靠合作伙伴。

Clininvent Research Pvt. Ltd.，作为TCG Lifesciences的一部分，继续为药物发现、开发和商业化提供端到端解决方案。该公司专注于定制制造和监管合规，特别是通过FDA批准的设施，确保他们满足制药行业严格的质量要求。

他们在GMP（良好生产规范）合规和临床试验管理方面的专业知识进一步巩固了他们在印度不断增长的CRO生态系统中的角色。

## Report Scope

| 市场规模 2024 | 63.2（亿美元） |
| --- | --- |
| 市场规模 2025 | 67.4（亿美元） |
| 市场规模 2035 | 120.0（亿美元） |
| 年复合增长率（CAGR） | 6.0%（2024 - 2035） |
| 报告覆盖范围 | 收入预测、竞争格局、增长因素和趋势 |
| 基准年 | 2024 |
| 市场预测期 | 2025 - 2035 |
| 历史数据 | 2019 - 2024 |
| 市场预测单位 | 亿美元 |
| 关键公司简介 | IQVIA（印度）、Syneos Health（印度）、PAREXEL International（印度）、Covance（印度）、Charles River Laboratories（印度）、Medpace（印度）、Clinipace（印度）、KCR（印度）、Pharmalex（印度） |
| 覆盖的细分市场 | 应用、服务类型、最终用途 |
| 关键市场机会 | 印度合同研究组织市场对创新药物开发和个性化医疗的需求上升。 |
| 关键市场动态 | 对创新疗法的需求上升推动印度合同研究组织市场的增长，伴随监管演变。 |
| 覆盖的国家 | 印度 |

## Frequently Asked Questions

**Q: 印度合同研究组织市场的当前估值是多少？**
A: 市场估值在2024年为63.2亿美元。

**Q: 到2035年，印度合同研究组织市场的预计市场规模是多少？**
A: 预计到2035年，市场将达到120亿美元。

**Q: 在预测期内，印度合同研究组织市场的预期年均增长率是多少？**
A: 预计2025年至2035年间市场的年均增长率为6.0%。

**Q: 印度合同研究组织市场按应用包括哪些细分领域？**
A: 细分领域包括临床试验、临床前研究、实验室服务、数据管理和监管事务。

**Q: 印度合同研究组织市场中临床试验的预计估值是多少？**
A: 临床试验预计将从2024年的25.2亿美元增长到2035年的48亿美元。

**Q: 印度合同研究组织市场的主要参与者是谁？**
A: 主要参与者包括IQVIA、Syneos Health、PAREXEL International、Covance和Charles River Laboratories。

**Q: 印度合同研究组织市场的制药服务细分中提供哪些服务？**
A: 制药服务预计将从2024年的25.2亿美元增长到2035年的48亿美元。

**Q: 印度合同研究组织市场中生物技术服务的预期增长是多少？**
A: 生物技术服务预计将从2024年的12.6亿美元增长到2035年的24亿美元。

**Q: 印度合同研究组织市场中包括哪些最终用途细分？**
A: 最终用途细分包括制药公司、生物技术公司、学术机构和政府组织。

**Q: 印度合同研究组织市场中监管事务的预计增长是多少？**
A: 监管事务预计将从2024年的4.4亿美元增长到2035年的8亿美元。


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/india-cro-market-2927*